Kala Pharmaceuticals, Inc. (KALA)

Market Cap	18.03M
Revenue (ttm)	n/a
Net Income (ttm)	-42.20M
Shares Out	2.82M
EPS (ttm)	-17.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	957
Open	6.47
Previous Close	6.50
Day's Range	6.40 - 6.51
52-Week Range	5.10 - 19.35
Beta	-1.84
Analysts	Strong Buy
Price Target	18.00 (+181.25%)
Earnings Date	May 7, 2024

About KALA

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical d...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA

Analyst Forecast

According to 2 analysts, the average rating for KALA stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 181.25% from the latest price.

Price Target

$18.0

(181.25% upside)

Analyst Consensus: Strong Buy